Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 223,800 shares, a decrease of 37.6% from the March 31st total of 358,600 shares. Based on an average daily trading volume, of 368,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 3.5% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets lowered their target price on shares of Alzamend Neuro from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, March 17th.

Alzamend Neuro Stock Performance

Shares of NASDAQ:ALZN opened at $0.66 on Thursday. Alzamend Neuro has a 52 week low of $0.64 and a 52 week high of $15.06. The company has a 50-day moving average price of $0.82 and a 200 day moving average price of $1.13.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. On average, research analysts forecast that Alzamend Neuro will post -1.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC purchased a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro at the end of the most recent quarter. 49.61% of the stock is currently owned by hedge funds and other institutional investors.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.